Literature DB >> 22870428

Febuxostat treatment for gout: what the clinician needs to know.

Lan X Chen1, H Ralph Schumacher.   

Abstract

Febuxostat is a new non-purine based inhibitor of xanthine oxidase that will be a useful addition to the drugs available to treat gout. This short review covers general principles of the management of gout and then focuses on practical aspects and use of febuxostat.

Entities:  

Keywords:  allopurinol; colchicine; febuxostat; gout; probenecid

Year:  2009        PMID： 22870428      PMCID： PMC3383484          DOI： 10.1177/1759720X09347037

Source DB:  PubMed          Journal:  Ther Adv Musculoskelet Dis        ISSN： 1759-720X            Impact factor:   5.346


  22 in total

1.  Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis.

Authors:  Aarti Malik; H Ralph Schumacher; Janet E Dinnella; Gilda M Clayburne
Journal:  J Clin Rheumatol       Date:  2009-02       Impact factor: 3.517

2.  The influence of temperature on the solubility of monosodium urate.

Authors:  J N Loeb
Journal:  Arthritis Rheum       Date:  1972 Mar-Apr

3.  Relation between adverse events associated with allopurinol and renal function in patients with gout.

Authors:  J Vázquez-Mellado; E M Morales; C Pacheco-Tena; R Burgos-Vargas
Journal:  Ann Rheum Dis       Date:  2001-10       Impact factor: 19.103

4.  Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

Authors:  Michael A Becker; H Ralph Schumacher; Robert L Wortmann; Patricia A MacDonald; Denise Eustace; William A Palo; Janet Streit; Nancy Joseph-Ridge
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

5.  Serum urate levels and gout flares: analysis from managed care data.

Authors:  Chaitanya A Sarawate; Pankaj A Patel; H Ralph Schumacher; Wenya Yang; Kathleen K Brewer; Alan W Bakst
Journal:  J Clin Rheumatol       Date:  2006-04       Impact factor: 3.517

6.  Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.

Authors:  Gregory C Borstad; Leslie R Bryant; Michael P Abel; Daren A Scroggie; Mark D Harris; Jeff A Alloway
Journal:  J Rheumatol       Date:  2004-12       Impact factor: 4.666

7.  Tophaceous joint disease strongly predicts hand function in patients with gout.

Authors:  N Dalbeth; J Collis; K Gregory; B Clark; E Robinson; F M McQueen
Journal:  Rheumatology (Oxford)       Date:  2007-11-03       Impact factor: 7.580

8.  Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.

Authors:  K R Hande; R M Noone; W J Stone
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

9.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II.

Authors:  Reva C Lawrence; David T Felson; Charles G Helmick; Lesley M Arnold; Hyon Choi; Richard A Deyo; Sherine Gabriel; Rosemarie Hirsch; Marc C Hochberg; Gene G Hunder; Joanne M Jordan; Jeffrey N Katz; Hilal Maradit Kremers; Frederick Wolfe
Journal:  Arthritis Rheum       Date:  2008-01

10.  A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.

Authors:  M K Reinders; C Haagsma; T L Th A Jansen; E N van Roon; J Delsing; M A F J van de Laar; J R B J Brouwers
Journal:  Ann Rheum Dis       Date:  2008-07-16       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.